{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:27:32Z","timestamp":1789504052340,"version":"build-2803163510"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:00:00Z","timestamp":1719187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009754","name":"Galderma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009754","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>RelabotulinumtoxinA (RelaBoNT-A, Galderma, Uppsala, Sweden) is an innovative, ready-to-use liquid botulinum toxin A, produced with PEARL (precipitation-free extraction and activity-preserving refined liquid) manufacturing technology, which yields a potent, complex-free formulation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>In the READY-1 study, efficacy and safety outcomes following a single RelaBoNT-A treatment for glabellar line correction were examined.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Adults with moderate to severe glabellar lines received RelaBoNT-A (50 U) or placebo in a 3:1 randomized, 6-month, phase 3, multicenter, double-blind study. Primary endpoints (examined at Month 1, maximum frown) comprised the composite \u22652-grade response, defined as \u22652-grades improvement from baseline on concurrent investigator (glabellar line investigator live assessment; GL-ILA) and participant (glabellar line subject live assessment; GL-SLA) severity scales (US endpoint), and the investigator-reported responder rate for participants scored as 0 (none) or 1 (mild) (GL-ILA scale only; EU endpoint). Participant satisfaction and treatment-emergent adverse events (TEAEs) were reported.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, 297 adults were randomized and treated. Month 1 composite \u22652-grade responder rate was 82.9% (RelaBoNT-A, n = 199) vs 0% (placebo, n = 67; P &amp;lt; .001). Month 1 investigator-reported none or mild responder rate was 96.3% (RelaBoNT-A) vs 4.5% (placebo; P &amp;lt; .001). GL-ILA scores remained higher with RelaBoNT-A (23.6% [none or mild]; 58.1% [\u22651-grade improvement]) vs placebo (1.5%; 10.4%, respectively) through Month 6 (P &amp;lt; .001). In the Kaplan-Meier analysis, 75% still showed GL-ILA and GL-SLA improvements from baseline at 169 days (end of study). Participants reported onset of effect from Day 1 (39%) and satisfaction with natural-looking results (96.8%; Month 1). RelaBoNT-A\u2013related TEAEs were low (3.6%) and typically mild.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>A single RelaBoNT-A treatment was effective and demonstrated a favorable safety profile. RelaBoNT-A provided significant improvements in glabellar line severity, high satisfaction, rapid onset, and enduring effectiveness throughout the 6-month study period.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Level of Evidence: 1<\/jats:title>\n                  <jats:p\/>\n               <\/jats:sec>","DOI":"10.1093\/asj\/sjae131","type":"journal-article","created":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T16:11:36Z","timestamp":1719245496000},"page":"1330-1340","source":"Crossref","is-referenced-by-count":15,"title":["Efficacy and Safety of RelabotulinumtoxinA, a New Ready-to-Use Liquid Formulation Botulinum Toxin: Results From the READY-1 Double-Blind, Randomized, Placebo-Controlled Phase 3 Trial in Glabellar Lines"],"prefix":"10.1093","volume":"44","author":[{"given":"Sachin M","family":"Shridharani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Moradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Donofrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Biesman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalyn","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristel","family":"Polder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nowell","family":"Solish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Schwarcz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Ax\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inna","family":"Prygova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,6,24]]},"reference":[{"key":"2024111514152227000_sjae131-B1","author":"Aesthetic Society"},{"key":"2024111514152227000_sjae131-B2","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2147\/cia.s9338","article-title":"Treating glabellar lines with botulinum toxin type A-hemagglutinin complex: a review of the science, the clinical data, and patient satisfaction","volume":"5","author":"De Boulle","year":"2010","journal-title":"Clin Interv Aging"},{"issue":"1 Suppl","key":"2024111514152227000_sjae131-B3","doi-asserted-by":"publisher","first-page":"13S","DOI":"10.1177\/1090820X12474632","article-title":"A review of AbobotulinumtoxinA (Dysport)","volume":"33","author":"Lorenc","year":"2013","journal-title":"Aesthet Surg J"},{"issue":"1","key":"2024111514152227000_sjae131-B4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/DSS.0000000000002013","article-title":"Efficacy, safety, and subject satisfaction after AbobotulinumtoxinA treatment for moderate to severe glabellar lines","volume":"46","author":"Monheit","year":"2020","journal-title":"Dermatol Surg"},{"issue":"4","key":"2024111514152227000_sjae131-B5","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1097\/DSS.0000000000002846","article-title":"A multicenter study to evaluate subject satisfaction with two treatments of AbobotulinumtoxinA a year in the glabellar lines","volume":"47","author":"Schlessinger","year":"2021","journal-title":"Dermatol Surg"},{"issue":"9","key":"2024111514152227000_sjae131-B6","doi-asserted-by":"publisher","first-page":"988","DOI":"10.36849\/jdd.6130","article-title":"AbobotulinumtoxinA treatment of glabellar lines using a new reconstitution and injection volume: randomized, placebo-controlled data","volume":"20","author":"Schlessinger","year":"2021","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"2024111514152227000_sjae131-B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7181\/acfs.2021.00003","article-title":"Scientific review of the aesthetic uses of botulinum toxin type A","volume":"22","author":"Park","year":"2021","journal-title":"Arch Craniofac Surg"},{"key":"2024111514152227000_sjae131-B8","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2147\/CCID.S156851","article-title":"Botulinum neurotoxin formulations: overcoming the confusion","volume":"11","author":"Samizadeh","year":"2018","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"2024111514152227000_sjae131-B9","author":"Revance Therapeutics Inc"},{"key":"2024111514152227000_sjae131-B10","author":"Merz Pharmaceuticals L"},{"key":"2024111514152227000_sjae131-B11","author":"Evolus Inc"},{"key":"2024111514152227000_sjae131-B12","author":"Allergan Inc"},{"key":"2024111514152227000_sjae131-B13","author":"Ipsen Biopharm Ltd"},{"key":"2024111514152227000_sjae131-B14","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.16359","article-title":"Ready-to-use AbobotulinumtoxinA solution versus powder BotulinumtoxinA for treatment of glabellar lines: investigators\u2019 and subjects\u2019 experience in a phase IV study","author":"Chadha","year":"2024","journal-title":"J Cosmet Dermatol"},{"key":"2024111514152227000_sjae131-B15","author":"Liljegren Sundberg"},{"key":"2024111514152227000_sjae131-B16","author":"Hosseini"},{"key":"2024111514152227000_sjae131-B17","doi-asserted-by":"publisher","first-page":"325","DOI":"10.2147\/BTT.S14902","article-title":"Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?","volume":"4","author":"Frevert","year":"2010","journal-title":"Biologics"},{"issue":"7","key":"2024111514152227000_sjae131-B18","doi-asserted-by":"publisher","first-page":"494","DOI":"10.3390\/toxins13070494","article-title":"Botulinum toxin type A for glabellar frown lines: what impact of higher doses on outcomes?","volume":"13","author":"Kaufman-Janette","year":"2021","journal-title":"Toxins (Basel)"},{"issue":"suppl_1","key":"2024111514152227000_sjae131-B19","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1093\/asj\/sjw282","article-title":"Key parameters for the use of AbobotulinumtoxinA in aesthetics: onset and duration","volume":"37","author":"Nestor","year":"2017","journal-title":"Aesthet Surg J"},{"issue":"6","key":"2024111514152227000_sjae131-B20","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1007\/s00266-018-1200-4","article-title":"Assessment of subject and physician satisfaction after long-term treatment of glabellar lines with AbobotulinumtoxinA (Dysport\u00ae\/Azzalure\u00ae): primary results of the APPEAL noninterventional study","volume":"42","author":"Gubanova","year":"2018","journal-title":"Aesthetic Plast Surg"},{"issue":"6 Suppl","key":"2024111514152227000_sjae131-B21","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1016\/j.asj.2009.09.012","article-title":"An analysis of efficacy data from four phase III studies of botulinum neurotoxin type A-ABO for the treatment of glabellar lines","volume":"29","author":"Baumann","year":"2009","journal-title":"Aesthet Surg J"},{"issue":"1","key":"2024111514152227000_sjae131-B22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/PRS.0000000000006327","article-title":"DaxibotulinumtoxinA for injection for the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2)","volume":"145","author":"Carruthers","year":"2020","journal-title":"Plast Reconstr Surg"},{"issue":"6","key":"2024111514152227000_sjae131-B23","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1067\/mjd.2002.121356","article-title":"A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines","volume":"46","author":"Carruthers","year":"2002","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"2024111514152227000_sjae131-B24","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1097\/01.PRS.0000076504.79727.62","article-title":"Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines","volume":"112","author":"Carruthers","year":"2003","journal-title":"Plast Reconstr Surg"},{"issue":"11","key":"2024111514152227000_sjae131-B25","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1097\/DSS.0000000000001903","article-title":"Efficacy and safety of PrabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results from 2 identical phase III studies","volume":"45","author":"Beer","year":"2019","journal-title":"Dermatol Surg"},{"issue":"4","key":"2024111514152227000_sjae131-B26","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1093\/asj\/sjz110","article-title":"A multicenter, randomized, double-blind, placebo-controlled, single-dose, phase III, non-inferiority study comparing PrabotulinumtoxinA and OnabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult patients","volume":"40","author":"Rzany","year":"2020","journal-title":"Aesthet Surg J"},{"issue":"4","key":"2024111514152227000_sjae131-B27","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/dsu.12100","article-title":"Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines","volume":"39","author":"Carruthers","year":"2013","journal-title":"Dermatol Surg"},{"issue":"6","key":"2024111514152227000_sjae131-B28","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/dsu.12160","article-title":"A randomized, placebo-controlled, double-blind phase III trial investigating the efficacy and safety of incobotulinumtoxinA in the treatment of glabellar frown lines using a stringent composite endpoint","volume":"39","author":"Hanke","year":"2013","journal-title":"Dermatol Surg"},{"issue":"5","key":"2024111514152227000_sjae131-B29","first-page":"439","article-title":"The efficacy and safety of a new U.S. Botulinum toxin type A in the retreatment of glabellar lines following open-label treatment","volume":"8","author":"Rubin","year":"2009","journal-title":"J Drugs Dermatol"}],"container-title":["Aesthetic Surgery Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/asj\/advance-article-pdf\/doi\/10.1093\/asj\/sjae131\/58721187\/sjae131.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/asj\/article-pdf\/44\/12\/1330\/60683078\/sjae131.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/asj\/article-pdf\/44\/12\/1330\/60683078\/sjae131.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T14:16:06Z","timestamp":1731680166000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/asj\/article\/44\/12\/1330\/7697878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,24]]},"references-count":29,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,6,24]]},"published-print":{"date-parts":[[2024,11,15]]}},"URL":"https:\/\/doi.org\/10.1093\/asj\/sjae131","relation":{},"ISSN":["1090-820X","1527-330X"],"issn-type":[{"value":"1090-820X","type":"print"},{"value":"1527-330X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,6,24]]}}}